• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机临床试验中风险比的因果解释。

Causal interpretation of the hazard ratio in randomized clinical trials.

机构信息

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.

Department of Biostatistics and Center for Methods in Implementation and Prevention Science, Yale School of Public Health, New Haven, CT, USA.

出版信息

Clin Trials. 2024 Oct;21(5):623-635. doi: 10.1177/17407745241243308. Epub 2024 Apr 28.

DOI:10.1177/17407745241243308
PMID:38679930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11502288/
Abstract

BACKGROUND

Although the hazard ratio has no straightforward causal interpretation, clinical trialists commonly use it as a measure of treatment effect.

METHODS

We review the definition and examples of causal estimands. We discuss the causal interpretation of the hazard ratio from a two-arm randomized clinical trial, and the implications of proportional hazards assumptions in the context of potential outcomes. We illustrate the application of these concepts in a synthetic model and in a model of the time-varying effects of COVID-19 vaccination.

RESULTS

We define causal estimands as having either an or interpretation. Difference-in-expectation estimands are both individual-level and population-level estimands, whereas without strong untestable assumptions the causal rate ratio and hazard ratio have only population-level interpretations. We caution users against making an incorrect individual-level interpretation, emphasizing that in general a hazard ratio does not on average change each individual's hazard by a factor. We discuss a potentially valid interpretation of the constant hazard ratio as a population-level causal effect under the proportional hazards assumption.

CONCLUSION

We conclude that the population-level hazard ratio remains a useful estimand, but one must interpret it with appropriate attention to the underlying causal model. This is especially important for interpreting hazard ratios over time.

摘要

背景

尽管危害比没有直接的因果解释,但临床试验研究者通常将其用作治疗效果的衡量标准。

方法

我们回顾了因果估计量的定义和示例。我们讨论了来自两臂随机临床试验的危害比的因果解释,以及潜在结果背景下比例风险假设的含义。我们通过一个综合模型和 COVID-19 疫苗时变效应的模型说明了这些概念的应用。

结果

我们将因果估计量定义为具有 或 解释。差异预期估计量既是个体水平又是群体水平的估计量,而没有强有力的不可检验的假设,因果率比和危害比只有群体水平的解释。我们警告用户不要进行错误的个体水平解释,强调一般来说,危害比不会平均使每个人的危险增加一个因素。我们讨论了在比例风险假设下,恒定危害比作为群体水平因果效应的一种潜在有效解释。

结论

我们的结论是,群体水平的危害比仍然是一个有用的估计量,但必须根据潜在的因果模型进行适当的解释。这对于随时间解释危害比尤其重要。

相似文献

1
Causal interpretation of the hazard ratio in randomized clinical trials.随机临床试验中风险比的因果解释。
Clin Trials. 2024 Oct;21(5):623-635. doi: 10.1177/17407745241243308. Epub 2024 Apr 28.
2
The built-in selection bias of hazard ratios formalized using structural causal models.使用结构因果模型形式化的风险比的内在选择偏差。
Lifetime Data Anal. 2024 Apr;30(2):404-438. doi: 10.1007/s10985-024-09617-y. Epub 2024 Feb 15.
3
Bias of the additive hazard model in the presence of causal effect heterogeneity.存在因果效应异质性时相加风险模型的偏差。
Lifetime Data Anal. 2024 Apr;30(2):383-403. doi: 10.1007/s10985-024-09616-z. Epub 2024 Mar 11.
4
Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.在存在不依从性的随机试验中评估安全性上限的因果推断方法。
Clin Trials. 2015 Jun;12(3):265-75. doi: 10.1177/1740774515572352. Epub 2015 Mar 1.
5
Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.单世界干预图在临床试验中定义、识别和沟通目标值的应用。
Stat Med. 2023 Sep 20;42(21):3892-3902. doi: 10.1002/sim.9833. Epub 2023 Jun 21.
6
Translating questions to estimands in randomized clinical trials with intercurrent events.在伴有中间事件的随机临床试验中,将问题转化为评估目标。
Stat Med. 2022 Jul 20;41(16):3211-3228. doi: 10.1002/sim.9398. Epub 2022 May 16.
7
Identification and Estimation of Causal Effects Using Non-Concurrent Controls in Platform Trials.在平台试验中使用非同期对照进行因果效应的识别与估计
Stat Med. 2025 Mar 15;44(6):e70017. doi: 10.1002/sim.70017.
8
Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.事件发生时间终点的治疗效果量化——估计量、分析策略及其他。
Pharm Stat. 2019 Mar;18(2):145-165. doi: 10.1002/pst.1917. Epub 2018 Nov 26.
9
Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.在因果推理框架下,使用依从性因果估计量来实现三方估计量。
Pharm Stat. 2021 Jan;20(1):55-67. doi: 10.1002/pst.2054. Epub 2020 Aug 10.
10
A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.不同人群水平汇总指标在时间事件结局随机试验中的比较,重点关注非劣效性试验。
Clin Trials. 2023 Dec;20(6):594-602. doi: 10.1177/17407745231181907. Epub 2023 Jun 20.

引用本文的文献

1
Correcting for bias due to mismeasured exposure in mediation analysis with a survival outcome.在生存结局的中介分析中校正因暴露测量错误导致的偏倚。
J R Stat Soc Ser C Appl Stat. 2025 Feb 14;74(4):969-993. doi: 10.1093/jrsssc/qlaf010. eCollection 2025 Nov.
2
Revisiting the hazards of hazard ratios through simulations and case studies.通过模拟和案例研究重新审视风险比的危害。
Eur J Epidemiol. 2025 Jul 3. doi: 10.1007/s10654-025-01245-6.
3
A new method for dealing with collider bias in the PWP model for recurrent events in randomized controlled trials.

本文引用的文献

1
Eliminating Ambiguous Treatment Effects Using Estimands.利用目标治疗估计值消除模糊的治疗效果。
Am J Epidemiol. 2023 Jun 2;192(6):987-994. doi: 10.1093/aje/kwad036.
2
A sensitivity analysis approach for the causal hazard ratio in randomized and observational studies.随机对照研究和观察性研究中因果风险比的敏感性分析方法。
Biometrics. 2023 Sep;79(3):2743-2756. doi: 10.1111/biom.13797. Epub 2022 Nov 29.
3
Addressing Extreme Propensity Scores in Estimating Counterfactual Survival Functions via the Overlap Weights.通过重叠权重解决极端倾向评分对反事实生存函数估计的影响。
一种在随机对照试验中处理复发事件的PWP模型中碰撞器偏差的新方法。
BMC Med Res Methodol. 2025 May 26;25(1):142. doi: 10.1186/s12874-025-02596-0.
4
Inverse Probability of Treatment Weighting Using the Propensity Score With Competing Risks in Survival Analysis.生存分析中使用倾向得分及竞争风险进行治疗权重的逆概率法
Stat Med. 2025 Feb 28;44(5):e70009. doi: 10.1002/sim.70009.
5
Reply to Heitjan's commentary.对海特扬评论的回复。
Clin Trials. 2024 Oct;21(5):638-639. doi: 10.1177/17407745241243311. Epub 2024 Apr 28.
Am J Epidemiol. 2022 May 20;191(6):1140-1151. doi: 10.1093/aje/kwac043.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.辉瑞-BioNTech 信使核糖核酸新冠病毒疫苗 6 个月的安全性和有效性
N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.
5
Propensity score weighting for covariate adjustment in randomized clinical trials.随机临床试验中用于协变量调整的倾向评分加权法。
Stat Med. 2021 Feb 20;40(4):842-858. doi: 10.1002/sim.8805. Epub 2020 Nov 10.
6
Survival analysis using a 5-step stratified testing and amalgamation routine (5-STAR) in randomized clinical trials.在随机临床试验中使用五步分层检验与合并程序(5-STAR)进行生存分析。
Stat Med. 2020 Dec 30;39(30):4724-4744. doi: 10.1002/sim.8750. Epub 2020 Sep 20.
7
Subtleties in the interpretation of hazard contrasts.风险对比解读中的细微差别。
Lifetime Data Anal. 2020 Oct;26(4):833-855. doi: 10.1007/s10985-020-09501-5. Epub 2020 Jul 11.
8
Analysis of covariance in randomized trials: More precision and valid confidence intervals, without model assumptions.随机试验中的协方差分析:更高的精度和有效的置信区间,无需模型假设。
Biometrics. 2019 Dec;75(4):1391-1400. doi: 10.1111/biom.13062. Epub 2019 Jun 3.
9
Limitations of hazard ratios in clinical trials.临床试验中风险比的局限性。
Eur Heart J. 2019 May 1;40(17):1378-1383. doi: 10.1093/eurheartj/ehy770.
10
Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.事件发生时间终点的治疗效果量化——估计量、分析策略及其他。
Pharm Stat. 2019 Mar;18(2):145-165. doi: 10.1002/pst.1917. Epub 2018 Nov 26.